Saturday 17 October 2026
Export CNSY’s income statement to Excel — free account
Cerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.70
0.18
−9.57%
Follow CNSY
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 5 | 4 | 1 | — | — | — | 3 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
124,324.19 | (19.64) | (25.57) | (25.48) | (52.07) | — | (29.33) | (62.33) | (112.16) | (44.87) |
P/S ratio |
1,114,110.82 | 4.04 | 0.91 | 0.48 | 1.43 | — | 15.44 | 1.18 | 1.31 | 7.61 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(37.86) | (45.83) | (60.63) | (59.18) | (121.37) | — | (66.24) | (146.04) | (268.21) | (107.82) |
P/Operating CF |
(1,246,647.44) | (2.57) | (1.09) | 3.21 | (2.77) | — | (3.64) | (3.09) | (6.31) | (6.34) |
Beneish M-Score |
(2.73) | (0.75) | (2.12) | 0.73 | — | — | — | — | — | (3.46) |
P/B ratio |
472,173.68 | 0.84 | 0.52 | 2.87 | 2.95 | — | 1.26 | 0.00 | 0.00 | 9.93 |
Price to Tangible BV |
0.00 | 5.81 | 0.56 | 4.23 | 3.47 | — | 1.36 | 0.00 | 0.00 | 12.06 |
EV/Sales |
1,114,111.84 | 8.20 | 6.50 | (0.37) | 1.19 | — | (8.71) | 1.02 | 1.91 | 6.80 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 1.16 | 0.00 | — | 0.25 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(265,566.21) | (1.22) | (1.62) | 0.43 | (0.88) | — | 0.35 | (0.39) | (1.05) | (1.71) |
EV/FCF |
(266,261.41) | (1.13) | (1.46) | 0.36 | (0.77) | — | 0.34 | (0.39) | (0.99) | (1.66) |
Quick Ratio |
1.13 | 0.56 | 0.31 | 1.30 | 0.98 | 3.13 | 1.53 | 0.80 | 0.27 | 1.09 |
Current Ratio |
1.50 | 0.81 | 0.55 | 1.37 | 1.07 | 3.36 | 1.84 | 0.92 | 0.34 | 1.23 |
Net Debt/EBITDA |
(0.27) | (0.19) | (1.44) | 2.66 | 0.17 | 1.02 | 0.68 | 0.37 | 0.02 | 0.83 |
Debt/Assets |
50.96% | 43.09% | 59.20% | 50.39% | 56.70% | 30.09% | 22.60% | 34.91% | 49.63% | 4.59% |
Debt/Equity |
1.61 | 1.05 | 2.72 | 10.09 | 2.26 | 0.61 | 0.84 | (2.95) | (0.37) | 0.19 |
Asset Turnover |
0.13 | 0.08 | 0.11 | 0.30 | 0.02 | 0.00 | 0.01 | 0.28 | 0.65 | 0.45 |
Operating CF/Net income |
0.89 | 0.68 | 0.79 | 0.52 | 1.02 | 0.77 | 0.64 | 0.97 | 0.81 | 0.93 |
Capex/Depreciation |
0.03 | (0.48) | (0.05) | (0.05) | (0.10) | (0.09) | (0.50) | (0.20) | (0.79) | (0.08) |
Interest Coverage |
(7.60) | (10.09) | (4.56) | (1.97) | (8.66) | (13.40) | (27.72) | (33.72) | (82.09) | (27.92) |
| (190.12%) | (222.32%) | (165.94%) | (358.37%) | (393.27%) | (193.25%) | (234.65%) | (522.50%) | 252.07% | 903.94% | |
| (60.98%) | (80.52%) | (54.39%) | (48.46%) | (46.65%) | (78.62%) | (88.44%) | (75.54%) | (144.03%) | (195.02%) | |
ROIC |
(78.38%) | (78.83%) | (38.77%) | 0.00% | (386.95%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(297.80%) | 5,354.02% | 269.44% | (152.18%) | (335.55%) | (87.40%) | (179.60%) | (102,430.77%) | 131.84% | (719.11%) |
Average Days of Receivables |
97.36 | 19.68 | 21.78 | 60.97 | 0.00 | — | 0.00 | 0.00 | 35.79 | 22.55 |
Research and Development Expense of Revenue |
347.87% | 434.29% | 185.15% | 76.66% | 891.09% | 0.00% | 4,329.46% | 197.23% | 181.66% | 160.73% |
Selling, General and Administrative Expense of Revenue |
261.47% | 416.03% | 208.58% | 75.59% | 2,114.19% | 0.00% | 4,570.54% | 173.91% | 170.66% | 232.73% |
Intangible Assets out of Total Assets |
0.36 | 0.35 | 0.02 | 0.02 | 0.04 | 0.02 | 0.02 | 0.04 | 0.13 | 0.04 |
Share Based Compensation of Revenue |
23.20% | 28.00% | 11.90% | 1.81% | 81.52% | 0.00% | 270.54% | 11.58% | 9.44% | 29.54% |
Graham Net Nets |
0.00 | (0.34) | (3.35) | (0.67) | 0.01 | — | 0.54 | (0.50) | (1.35) | 0.07 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 162.26 | 197.59 | 0.00 |
Earnings Yield |
(224.78%) | (241.40%) | (6,969.93%) | (18,475.28%) | (92.09%) | — | (973.03%) | (235.74%) | (179.13%) | (237.25%) |
Free Cash Flow Yield |
0.00% | (179.41%) | (489.53%) | (215.44%) | (108.83%) | — | (167.10%) | (223.98%) | (147.26%) | (53.84%) |
Revenue per Share |
0.27 | 13,445.00 | 5,966.00 | 1,891.35 | 25.68 | 0.00 | 3.20 | 39.12 | 21.93 | 1.68 |
Operating CF per Share |
(1.13) | (90,640.00) | (23,950.00) | (1,596.22) | (714.75) | (318.27) | (185.31) | (102.32) | (39.74) | (6.68) |
Capex per Share |
0.00 | (6,915.00) | (266.00) | (18.11) | (7.88) | (2.54) | (7.27) | (1.27) | (2.60) | (0.01) |
Free Cash Flow per Share |
(1.13) | (97,555.00) | (24,216.00) | (1,614.32) | (722.63) | (320.80) | (192.59) | (103.59) | (42.34) | (6.69) |
Cash per Share |
0.75 | 51,125.00 | 10,602.00 | 4,754.59 | 707.29 | 569.66 | 258.86 | 68.11 | 13.58 | 4.21 |
Shareholders Equity per Share |
0.64 | 65,000.00 | 10,450.00 | 313.51 | 256.86 | 335.48 | 92.07 | (10.73) | (33.69) | 1.28 |
Interest Debt per Share |
0.00 | 0.07 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.64 | 65,000.00 | 10,450.00 | 313.51 | 256.86 | 335.48 | 92.07 | (10.73) | (33.69) | 1.28 |
Free Cash Flow |
(19.47) | (19.51) | (12.11) | (5.97) | (8.53) | (10.36) | (13.48) | (13.01) | (11.24) | (20.81) |
Working Capital |
6.25 | (3.55) | (7.91) | 5.34 | 0.64 | 13.85 | 9.97 | (0.89) | (10.29) | 2.86 |
Capital Expenditures |
0.06 | (1.38) | (0.13) | (0.07) | (0.09) | (0.08) | (0.51) | (0.16) | (0.69) | (0.04) |
Net Current Asset Value |
(4.88) | (3.75) | (9.12) | (2.24) | 0.10 | 8.58 | 4.40 | (2.90) | (10.32) | 2.84 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.70 | 0.00 | — | 0.23 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
(0.01) | 0.51 | 0.04 | 0.01 | 0.31 | 0.00 | 2.27 | 0.03 | 0.12 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.85 | 0.94 | 1.12 | 0.66 | 0.52 | 0.64 | 0.76 | 0.90 | 1.95 | 1.73 |
Cash ROIC |
(46.88%) | (52.95%) | (48.96%) | (19.61%) | (46.75%) | (28.90%) | (45.00%) | (116.36%) | 548.27% | (116.53%) |
Accounts Receivable Turnover |
4.06 | 3.88 | 18.47 | 10.39 | 0.00 | — | 0.00 | 0.00 | 6.69 | 11.68 |
Accounts Payable Turnover |
0.43 | 0.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.68 | 0.74 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
789.42 | 687.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
500.78 | 456.86 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.15 | 0.69 | 0.16 | 0.67 | — | — | — | — | 0.87 | 0.45 |
Average Payables |
6.28 | 5.33 | 3.78 | 3.03 | 2.68 | 3.12 | 7.14 | 8.38 | 8.96 | 8.60 |
Average Inventory |
4.01 | 3.45 | 1.65 | 0.11 | — | — | — | — | — | — |
Average Assets |
36.15 | 33.11 | 27.80 | 23.61 | 17.67 | 17.04 | 22.92 | 17.63 | 9.01 | 11.48 |
Average Common Equity |
11.60 | 11.99 | 9.11 | 3.19 | 2.10 | 6.93 | 8.64 | 2.55 | (5.15) | (2.48) |
Columns are period end dates